Preoperative and postoperative systemic therapy for operable non–small-cell lung cancer

JE Chaft, Y Shyr, B Sepesi, PM Forde - Journal of Clinical Oncology, 2022 - ascopubs.org
Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …

Hyperprogressive disease: recognizing a novel pattern to improve patient management

S Champiat, R Ferrara, C Massard, B Besse… - Nature Reviews …, 2018 - nature.com
Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …

Vorasidenib in IDH1-or IDH2-mutant low-grade glioma

IK Mellinghoff, MJ Van Den Bent… - … England Journal of …, 2023 - Mass Medical Soc
Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …

[HTML][HTML] The evolution of lung cancer and impact of subclonal selection in TRACERx

AM Frankell, M Dietzen, M Al Bakir, EL Lim, T Karasaki… - Nature, 2023 - nature.com
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE …

CM Rudin, MM Awad, A Navarro, M Gottfried… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-
cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo …

J Rech, K Tascilar, M Hagen, A Kleyer, B Manger… - The Lancet, 2024 - thelancet.com
Background Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical
inflammatory changes in joints are at high risk of develo** rheumatoid arthritis. Treatment …

Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis

NJ Short, S Zhou, C Fu, DA Berry, RB Walter… - JAMA …, 2020 - jamanetwork.com
Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …

Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial

D Schrag, H Uno, R Rosovsky, C Rutherford… - Jama, 2023 - jamanetwork.com
Importance In patients with cancer who have venous thromboembolism (VTE) events, long-
term anticoagulation with low-molecular-weight heparin (LMWH) is recommended to prevent …

Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement

AB Goldstone, P Chiu, M Baiocchi… - … England Journal of …, 2017 - Mass Medical Soc
Background In patients undergoing aortic-valve or mitral-valve replacement, either a
mechanical or biologic prosthesis is used. Biologic prostheses have been increasingly …

[PDF][PDF] The recombinant shingles vaccine is associated with lower risk of dementia

M Taquet, Q Dercon, JA Todd, PJ Harrison - Nature Medicine, 2024 - nature.com
There is emerging evidence that the live herpes zoster (shingles) vaccine might protect
against dementia. However, the existing data are limited and refer only to the live vaccine …